Recurrent CIC-rearranged sarcoma of central nervous system: a clinicopathological case report
CIC-rearranged sarcoma (CRS) is a subgroup of small round blue cell tumors similar to Ewing's sarcoma but lacking the EWSR1 gene translocation. It is characterized by a CIC gene rearrangement on chromosome 19q13, with the most common partner gene being DUX4. In 2021, the WHO classification of central nervous system tumors (5th edition) introduced a new pathological classification for CRS based on bone and soft tissue tumor classifications, categorizing it as mesenchymal non-meningeal epithelial tumors. Primary CIC::DUX4 rearrangement sarcoma in the central nervous system is extremely rare, with no established standard treatment and a very poor prognosis. Herein, we present a case of intracranial CIC::DUX4 rearrangement diagnosed using DNA methylation classifiers and multiple omics diagnosis techniques. We also document the disease progression after chemoradiation therapy and subsequent <i>in situ</i> recurrence.
Authors
- K. K. Li
- Houshi Xu (ORCID: https://orcid.org/0000-0002-2878-0913)
- Qisheng Tang (ORCID: https://orcid.org/0000-0003-2954-2797)
- Huihui Chai (ORCID: https://orcid.org/0000-0003-3704-2805)
- Maoyuan Sun (ORCID: https://orcid.org/0009-0003-1247-182X)
- Z Y Shi
- Bei-Ning Liu
- Jingqi Hu
- Rui-Ze Zhu
- Yue Wang
- Yun Guan
- Shan Jiang
Institutions
- Chinese University of Hong Kong (HK)
- Fudan University (CN)
- Ohkawara Neurosurgical Hospital (JP)
- Shanghai Clinical Research Center (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.3389/fonc.2025.1545700
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Fudan University
- Science and Technology Commission of Shanghai Municipality
- National Key Research and Development Program of China